Strategic Focus
Our strategy to target key aspects of EB
Epidermolysis bullosa (EB) has a wide range of symptoms and associated conditions. EB is not just a skin disease but has far-reaching effects on the entire body. Due to the complex clinical features of EB, research is focused on various key areas.
The current scientific focus of our R&D activities addresses dystrophic and junctional EB. These are the most severe forms of EB and carry a significantly increased risk of developing cutaneous squamous cell carcinoma (SCC).
EB is currently incurable. Our approaches are focusing on addressing skin fragility and the risk of developing EB-derived skin tumors. In the future, we plan to expand our research efforts to target blister and wound formation.
We are building an EB Biobank by systematically collecting and processing patient-derived biological samples alongside related clinical data. This allows us to generate unprecedent insight into pathogenic events in EB aiming to identify new relevant targets for drug discovery, to ultimately provide novel therapeutic options to EB patients.
We are advancing our efforts in EB in collaboration with other research institutions and clinics as well as industry partners.
